Phathom Pharmaceuticals Inc (PHAT NASDAQ) stock market data APIs
$8.8865
0.66(7.4%)
as of July 1, 2025
Try our APIs with
free plan!
Phathom Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Prev. Close
8.8865
Open
9.548
High
9.498
Low
8.7022
52 wk Range
2.21-19.71
Market Cap
670 M
Shares Outstanding
69 814 K
Revenue
81 859 K
EPS
-1.07
Beta
0.095
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Phathom Pharmaceuticals Inc data using free add-ons & libraries
Get Phathom Pharmaceuticals Inc Fundamental Data
Phathom Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 81 859 K
- EBITDA: -285 617 984
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -1.066
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Phathom Pharmaceuticals Inc News
New
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroi...
Phathom says FDA confirmed Voqueza exclusivity through May 2032
[FDA headquarters in Washington DC.] JHVEPhoto/iStock Editorial via Getty Images * Phathom Pharmaceuticals (NASDAQ:PHAT [https://seekingalpha.com/symbol/PHAT]) said that the U.S. FDA has updated it...
Phathom Pharma: FDA Updates Orange Book To Reflect 10 Year NCE Regulatory Exclusivity For VOQUEZNA
(RTTNews) - Phathom Pharmaceuticals, Inc. (PHAT) announced Monday that the U.S. Food and Drug Administration has updated the Approved Drug Products with Therapeutic Equivalence Evaluations, i.e., the ...
Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032
FLORHAM PARK, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroi...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
